Ibrahima Diouf1, Ashley I Bush2, Scott Ayton3. 1. Melbourne Dementia Research Centre, The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia; CSIRO Health and Biosecurity/Australian E-Health Research Centre, Brisbane, Australia. 2. Melbourne Dementia Research Centre, The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia. 3. Melbourne Dementia Research Centre, The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia. Electronic address: scott.ayton@florey.edu.au.
Abstract
OBJECTIVES: The mechanisms leading to neurodegeneration in Alzheimer's disease (AD) may involve oxidative stress and neuroinflammation. Ceruloplasmin (Cp) is a circulating protein that intersects both these pathways, since its expression is increased during the acute phase response, and the protein acts to lower pro-oxidant iron in cells. Since the role of Cp in AD, and its potential for use as a biomarker is not established, we investigated CSF Cp and its association with longitudinal outcome measures related to AD. METHODS: This was an observational study of 268 people from the Alzheimer's Disease Neuroimaging (ADNI) cohort. Subjects were classified clinically as having AD, mild cognitive impairment (MCI) or were cognitively normal (CN), and were also classified as being positive for β-amyloid using established thresholds in the CSF t-tau/Aβ42 ratio. Subjects underwent cognitive tests and MRI studies every 6 months for 2 years, then yearly thereafter for up to 6 years. RESULTS: At baseline, CSF Cp was not associated with clinical or pathological diagnosis, but we found an unexpected association between CSF Cp and levels of CSF apolipoprotein E. In longitudinal analysis, high level of CSF Cp was associated with accelerated cognitive decline (as assessed by ADAS-Cog, CDR-SB, and MMSE) and ventricular volume enlargement in people classified as MCI and who had underlying β-amyloid pathology. CONCLUSION: These results raise new questions into the role of Cp in neuroinflammation, oxidative stress, and APOE pathways involved in AD, and reveal the potential for this protein to be used as a biomarker in disease prognostication.
OBJECTIVES: The mechanisms leading to neurodegeneration in Alzheimer's disease (AD) may involve oxidative stress and neuroinflammation. Ceruloplasmin (Cp) is a circulating protein that intersects both these pathways, since its expression is increased during the acute phase response, and the protein acts to lower pro-oxidant iron in cells. Since the role of Cp in AD, and its potential for use as a biomarker is not established, we investigated CSFCp and its association with longitudinal outcome measures related to AD. METHODS: This was an observational study of 268 people from the Alzheimer's Disease Neuroimaging (ADNI) cohort. Subjects were classified clinically as having AD, mild cognitive impairment (MCI) or were cognitively normal (CN), and were also classified as being positive for β-amyloid using established thresholds in the CSF t-tau/Aβ42 ratio. Subjects underwent cognitive tests and MRI studies every 6 months for 2 years, then yearly thereafter for up to 6 years. RESULTS: At baseline, CSFCp was not associated with clinical or pathological diagnosis, but we found an unexpected association between CSFCp and levels of CSFapolipoprotein E. In longitudinal analysis, high level of CSFCp was associated with accelerated cognitive decline (as assessed by ADAS-Cog, CDR-SB, and MMSE) and ventricular volume enlargement in people classified as MCI and who had underlying β-amyloid pathology. CONCLUSION: These results raise new questions into the role of Cp in neuroinflammation, oxidative stress, and APOE pathways involved in AD, and reveal the potential for this protein to be used as a biomarker in disease prognostication.
Authors: John Q Trojanowski; Hugo Vandeerstichele; Magdalena Korecka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Z Potter; Michael W Weiner; Clifford R Jack; William Jagust; Arthur W Toga; Virginia M-Y Lee; Leslie M Shaw Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2011-11-02 Impact factor: 21.566
Authors: Alan Rembach; James D Doecke; Blaine R Roberts; Andrew D Watt; Noel G Faux; Irene Volitakis; Kelly K Pertile; Rebecca L Rumble; Brett O Trounson; Christopher J Fowler; William Wilson; Kathryn A Ellis; Ralph N Martins; Christopher C Rowe; Victor L Villemagne; David Ames; Colin L Masters; Ashley I Bush Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472
Authors: Scott Ayton; Peng Lei; James A Duce; Bruce X W Wong; Amelia Sedjahtera; Paul A Adlard; Ashley I Bush; David I Finkelstein Journal: Ann Neurol Date: 2013-02-19 Impact factor: 10.422
Authors: Scott Ayton; Amir Fazlollahi; Pierrick Bourgeat; Parnesh Raniga; Amanda Ng; Yen Ying Lim; Ibrahima Diouf; Shawna Farquharson; Jurgen Fripp; David Ames; James Doecke; Patricia Desmond; Roger Ordidge; Colin L Masters; Christopher C Rowe; Paul Maruff; Victor L Villemagne; Olivier Salvado; Ashley I Bush Journal: Brain Date: 2017-08-01 Impact factor: 13.501
Authors: Q-Z Tuo; P Lei; K A Jackman; X-L Li; H Xiong; X-L Li; Z-Y Liuyang; L Roisman; S-T Zhang; S Ayton; Q Wang; P J Crouch; K Ganio; X-C Wang; L Pei; P A Adlard; Y-M Lu; R Cappai; J-Z Wang; R Liu; A I Bush Journal: Mol Psychiatry Date: 2017-09-08 Impact factor: 15.992
Authors: Sarah Westwood; Alison L Baird; Abdul Hye; Nicholas J Ashton; Alejo J Nevado-Holgado; Sneha N Anand; Benjamine Liu; Danielle Newby; Chantal Bazenet; Steven J Kiddle; Malcolm Ward; Ben Newton; Keyur Desai; Cristina Tan Hehir; Michelle Zanette; Daniela Galimberti; Lucilla Parnetti; Alberto Lleó; Susan Baker; Vaibhav A Narayan; Wiesje M van der Flier; Philip Scheltens; Charlotte E Teunissen; Pieter Jelle Visser; Simon Lovestone Journal: Front Aging Neurosci Date: 2018-12-11 Impact factor: 5.750
Authors: Puja Agarwal; Scott Ayton; Sonal Agrawal; Klodian Dhana; David A Bennett; Lisa L Barnes; Sue E Leurgans; Ashley I Bush; Julie A Schneider Journal: Mol Psychiatry Date: 2022-10-04 Impact factor: 13.437
Authors: Keith W VanDusen; Yi-Ju Li; Victor Cai; Ashley Hall; Sarah Hiles; J Will Thompson; M Arthur Moseley; Mary Cooter; Leah Acker; Jerrold H Levy; Kamrouz Ghadimi; Quintin J Quiñones; Michael J Devinney; Stacey Chung; Niccolò Terrando; Eugene W Moretti; Jeffrey N Browndyke; Joseph P Mathew; Miles Berger Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472